Clinical Trial Update: ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of ASTX727 (oral decitabine/cedazuridine) with dasatinib for newly diagnosed Philadelphia chromosome-positive …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• ASTX727 (cedazuridine/decitabine)
• Sprycel (dasatinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Chronic Phase Chronic Myelogenous Leukemia, Philadelphia Chromosome Positive | Phase 2 | Status: RECRUITING